Clinical and electrophysiologic features of BIPN
| Clinical symptoms . | Electrophysiologic findings . |
|---|---|
| Often, mild to moderate distal sensory loss, suppression of deep tendon reflexes, proprioception abnormalities | NCS: Reduction of a-SAPs and CMAPs. Mild distal slowing of sensory and motor conduction velocities and increase in distal motor latencies. |
| Mild to very severe pain, mainly at fingertips and toes | EMG: Active denervation changes with fibrillation potentials and increased size and complexity of motor unit potentials from distal muscles of the lower limbs. |
| Usually, mild motor weakness in distal muscles of the lower limbs; rarely, severe distal and proximal weakness | QST: Increased touch thresholds, increased slotted pegboard time, cold pain thresholds at abnormally warm levels and reduction in sharpness detection |
| Very rarely, autonomic failure |
| Clinical symptoms . | Electrophysiologic findings . |
|---|---|
| Often, mild to moderate distal sensory loss, suppression of deep tendon reflexes, proprioception abnormalities | NCS: Reduction of a-SAPs and CMAPs. Mild distal slowing of sensory and motor conduction velocities and increase in distal motor latencies. |
| Mild to very severe pain, mainly at fingertips and toes | EMG: Active denervation changes with fibrillation potentials and increased size and complexity of motor unit potentials from distal muscles of the lower limbs. |
| Usually, mild motor weakness in distal muscles of the lower limbs; rarely, severe distal and proximal weakness | QST: Increased touch thresholds, increased slotted pegboard time, cold pain thresholds at abnormally warm levels and reduction in sharpness detection |
| Very rarely, autonomic failure |
BIPN indicates bortezomib-induced peripheral neuropathy; NCS, nerve conduction study; a-SAPs, amplitude of sensory action potentials; CMAPs, compound muscle action potentials; EMG, electromyography; and QST, quantitative sensory testing.